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Abstract 
Obstructive sleep apnea (OSA) affects mil-
lions of Americans and is estimated to be as
prevalent as asthma and diabetes. Given the
fact that obesity is a major risk factor for OSA,
and given the current global rise in obesity, the
prevalence of OSA will increase in the future.
Individuals  with  sleep  apnea  are  often
unaware of their sleep disorder. It is usually
first recognized as a problem by family mem-
bers  who  witness  the  apneic  episodes  or  is
suspected by their primary care doctor because
of the individual’s risk factors and symptoms.
The  vast  majority  remain  undiagnosed  and
untreated,  despite  the  fact  that  this  serious
disorder  can  have  significant  consequences.
Individuals  with  untreated  OSA  can  stop
breathing  hundreds  of  times  a  night  during
their sleep. These apneic events can lead to
fragmented sleep that is of poor quality, as the
brain arouses briefly in order for the body to
resume breathing. Untreated, sleep apnea can
have  dire  health  consequences  and  can
increase  the  risk  of  hypertension,  diabetes,
heart disease, and heart failure. OSA manage-
ment has also become important in a number
of comorbid neurological conditions, including
epilepsy,  stroke,  multiple  sclerosis,  and
headache. Diagnosis typically involves use of
screening questionnaires, physical exam, and
an  overnight  polysomnography  or  a  portable
home  study.  Treatment  options  include
changes in lifestyle, positive airway pressure,
surgery, and dental appliances.
Introduction
The Greek word apnea means breathless or
loss  of  breath.1 Sleep-disordered  breathing
(SDB) encompasses a heterogeneous group of
sleep-related disorders that are characterized
by abnormal pauses in breathing during sleep.
There are two major types of SDB: obstructive
sleep  apnea  (OSA)  and  central  sleep  apnea
(CSA).  Despite  the  difference  in  the  actual
cause of each type, in both cases, people with
untreated sleep apnea stop breathing repeat-
edly  during  their  sleep.  Of  the  two  types  of
sleep apneas characterized, OSA is the most
common type, constituting greater than 85% of
all cases of SBD; CSA is far less common.2
OSA is caused by a physical blockage of the
airway; it results from airflow obstruction sec-
ondary to upper airway collapse or anatomic
airway obstruction, even though the respirato-
ry effort is still present. In the case of CSA, the
airway is not blocked; the brain fails to signal
the muscles to breathe and breathing is inter-
rupted by a lack of respiratory effort.3
The clinical picture of OSA has long been
recognized in medical literature. It was first
described in 1918 by William Osler, a 20th cen-
tury  physician  who  coined  the  term
Pickwickian syndrome in reference to a char-
acter in Charles Dickens's novel The Pickwick
Papers. The character named Joe has all the
classic symptoms of the condition. Joe is con-
stantly  hungry,  red  faced  and  always  falling
asleep in the middle of doing a task.
The object that presented itself to the eyes of
the astonished clerk, was a boy - a wonderfully
fat  boy  -  habited  as  a  serving  lad,  standing
upright on the mat, with his eyes closed as if in
sleep.4
Epidemiology
OSA  affects  more  than  twelve  million
Americans.5 An  epidemiological  review  by
Young et al. estimates that 1 in 5 adults has at
least mild OSA and 1 in 15 adults has at least
moderate OSA.6 Sleep apnea can affect anyone
at any age, even children.7,8 OSA is becoming
increasingly  prevalent.  However,  because  of
the lack of awareness by the public and health-
care  professionals,  the  vast  majority  remain
undiagnosed  and  untreated.  Data  from  the
Wisconsin sleep cohort study of patients esti-
mate that 93% of women and 82% of men with
moderate-to-severe sleep apnea were undiag-
nosed.9 A  follow-up  publication  from  the
Wisconsin Cohort Study five years later indi-
cated  that  the  prevalence  of  OSA  in  people
aged 30-60 years was 9-24% for men and 4-9%
for women.10,11 Primary risk factors for OSA
include the male gender, those over age 40,
overweight persons or recent weight gain, and
persons  with  a  large  neck  size  or  small
chin/jaw (Table 1).12
Epidemiological  studies  have  consistently
shown that body weight, and in particular BMI,
is the strongest risk factor for OSA. It is esti-
mated that about 70% of those with OSA are
obese and that the prevalence of OSA in obese
men and women is about 40%.13,14 Twenty-six
percent of patients with a BMI greater than 30
and 33% of those with a BMI greater than 40
have moderate OSA.15 A large neck circumfer-
ence is also associated with an increased risk
of OSA. In fact, neck circumference of 15.7 in
(40 cm) or greater may have a greater sensitiv-
ity and specificity than BMI in predicting OSA,
regardless of the person’s sex.16,17
Age is also an important risk factor in the
development of OSA; the prevalence is estimat-
ed to triple in individuals greater than 65 years
of age compared with individuals aged 30-64
years.18,19 Regarding  gender,  the  male-to-
female  ratio  in  community-based  studies  is
about 3:1.20 It is theorized that body fat distri-
bution predispose men to OSA and that sex
hormones  play  a  role  in  the  modulation  of
upper airway musculature. 
As  indicated  above,  the  incidence  of  OSA
among  male  and  female  are  3:1  prior  to
menopause. However, the incidence of OSA is
equal  amongst  males  and  females  following
menopause.  There  is  at  least  a  threefold
increase  in  risk  of  OSA  among  post-
menopausal  women  compared  to  pre-
menopausal women.21,22 In addition, there is a
lower  prevalence  of  OSA  among  post-
menopausal  women  who  were  on  hormone
replacement  therapy.23 Interestingly,  there
does not appear to be any difference in preva-
lence  between  males  and  females  prior  to
puberty.
Structural  factors  related  to  craniofacial
bony anatomy can predispose patients to pha-
ryngeal collapse during sleep, including retrog-
nathia and micrognathia, mandibular hypopla-
sia, and high-arched palate.24,25 Imaging stud-
ies have demonstrated that patients with OSA
have  compromised  pharyngeal  lumens  that
predispose them to collapse.26 This was inde-
pendently confirmed under general anesthesia
that simulates the total muscle paralysis seen
during REM sleep.27 Patients with Down syn-
drome,  Marfan  syndrome,  and  Prader-Willi
syndrome are particularly at risk due to these
structural factors.
In terms of ethnicity, African American indi-
viduals appear to be more predisposed to OSA
than Caucasians, with an odds ratio of 3 in chil-
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than 25.28 Individuals of Asian descent, particu-
larly Chinese individuals, have a more crowded
upper airway and retrognathia compared with
Caucasians. OSA has a prevalence rate similar
in  the  Asian  population  sample  to  those  in
Caucasians despite a lower obesity rate. Asians
have  an  increased  risk  of  developing  OSA,
regardless of weight or neck circumference, as
well as greater disease severity.29
Pathophysiology  
The  International  Classification  of  Sleep
Disorders, second edition (ICSD-2) was pub-
lished  by  the  American  Academy  of  Sleep
Medicine to standardize definitions and create
a systematic approach to the diagnosis of sleep
disorders. The ICSD-2 subdivides sleep disor-
ders into eight major categories, one of which
is sleep-disorder breathing (SDB).30
The ICSD-2 further classifies SDB into three
basic  categories:  CSA  syndromes,  OSA  syn-
dromes,  and  sleep-related  hypoventilation/
hypoxic syndromes. OSA involves a complete
cessation or a significant decrease in airflow
in the presence of breathing effort. CSA is the
cessation of airflow with an absence of breath-
ing  effort.  Breathing  effort  is  measured  by
abdominal and/or chest movement.
The human airway is composed of soft tis-
sue that can collapse during REM sleep, when
the muscle tone of the body relaxes. Two major
factors likely contribute to OSA pathophysiolo-
gy: i) craniofacial structural abnormalities can
predispose patients to OSA; this has been dis-
cussed previously and has been recognized as
a primary risk factor for OSA; ii) larger soft tis-
sue mass or abnormal tissue deposits can also
increase  extraluminal  tissue  pressure  and
lower the threshold for airway collapse (Figure
1).  In  normal,  nonobese  individuals  without
OSA, muscle relaxation during sleep does not
completely  collapse  the  airway  (normal).
However,  airway  collapse  can  occur  during
muscle relaxation when there is a pathological
increase in tissue pressure, as a product of
extra  soft  tissue  mass  (in  a  normal-sized
enclosure) and/or structural limitations (small
maxillary  or  mandibular  compartment)  with
normal tissue mass (Figure 1).31 Chronically,
this dysfunction can cause problems with the
regulation of pharayngeal dilator muscle acti-
vation (which plays an important role in main-
taining airway patency) in patients with OSA.
OSA is thus characterized by the partial or
total collapse of the pharyngeal airway during
sleep and the need to arouse to resume venti-
lation.32 In  adults,  the  obstruction  typically
occurs  at  the  level  of  the  oropharynx
(uvula/soft  palate  or  tongue).33,34 Chronic
severe OSA can result in prolonged hypoxemia,
sleep  deprivation,  and  other  complications.
With  most  apneic  events,  the  brain  briefly
arouses in order for the body to resume breath-
ing, but consequently, sleep is extremely frag-
mented and of poor quality.
Several additional anatomical factors play a
role in OSA. These include the position that the
patient sleeps in, airway reactivity and airway
secretions. Position can have a strong influence
on airway patency. Because the airway is col-
lapsible,  gravitational  forces  can  cause  the
retropulsion of the tongue and soft palate while
laying supine, thus generating increased posi-
tive tissue pressure and narrowing the airway.35
For  this  reason,  OSA  worsens  in  the  supine
sleeping position for most individuals.36
Evaluation
Individuals  with  OSA  are  rarely  aware  of
their sleep disorder, even upon arousal.37Sleep
apnea is usually recognized as a problem by
family  members  who  witness  the  apneic
episodes or by a primary care doctor because of
the  individual’s  risk  factors  and  symptoms.
Most commonly, patients present with vague
complaints.  Clinical  symptoms  can  include
excessive daytime sleepiness (EDS) that usu-
ally begins during quiet activities (eg, reading,
watching television), daytime fatigue, feeling
tired  despite  a  full  night’s  sleep,  morning
headaches, personality and mood changes, dry
or  sore  throat,  gastroesophageal  reflux,  and
sexual dysfunction.
Snoring is a common finding in individuals
with OSA. Although not everyone who snores
is experiencing sleep apnea, snoring in combi-
nation with obesity has been found to be high-
ly predictive of OSA risk.38 The volume of the
snoring  is  not  indicative  of  the  severity  of
obstruction. However, snoring with witnessed
apneas has a 94% specificity for OSA.
The diagnosis of OSA is based on the evalu-
ation of clinical symptoms and risk factors, as
well  as  a  formal  sleep  study  evaluation
(polysomnography, or a portable home based
test). Individuals should be evaluated appro-
priately with screening questionnaires, as well
as a physical examination.
The  Epworth  sleepiness  scale  (ESS)  has
been  universally  adopted  as  an  effective
screening method to monitor for clinical symp-
toms  of  sleep  apnea.  This  questionnaire  is
used  to  help  determine  how  frequently  the
patient  is  likely  to  doze  off  in  8  frequently
encountered situations (e.g., as a passenger in
a car, sitting quietly after lunch, etc). A 2003
study  showed  that  an  ESS  score  of  12  or
greater is considered abnormal and would war-
rant a more formal evaluation.39 However, the
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Table 1. Primary risk factors for obstruc-
tive sleep apnea.
Primary risk factors for sleep apnea
Weight gain or being overweight with a BMI >30
kg/m2
Neck circumference [≥17in (or 43.2 cm) in men;
≥16in or (40.6 cm) in women]
Age >40
Male gender
Structural factors related to craniofacial anatomy
Ethnicity
Family history of sleep apnea
Figure 1. Reprinted with permission of the American Thoracic Society. Copyright (c) 2011
American Thoracic Society. White D. Pathogenesis of obstructive and central sleep apnea.
Am  J  Resp  Crit  Care  Med.  2005;  172:  1363-1370.  Official  Journal  of  the  American
Thoracic Society.ESS is still a subjective self assessment meas-
ure and may be inaccurate for a number of rea-
sons. Therefore, if a patient has multiple risk
factors for sleep apnea, the individual should
be sent for further evaluation if there is a sus-
picion of sleep apnea despite a low ESS.
Another  effective  screening  tool  that  has
been used in the primary care population is
the Berlin questionnaire.40 Survey questions
address  snoring  behavior,  EDS/fatigue,  and
history of obesity or hypertension. The sensi-
tivity of the Berlin questionnaire with regards
to high-risk patients having sleep apnea was
86%. Another screening tool called the STOP
BANG questionnaire was developed to screen
for the most common risk factors seen specifi-
cally in OSA. The term refers to a mnemonic
that represents 8 factors: Snoring, Tiredness,
Observed  apneas,  elevated  blood  Pressure,
BMI  (greater  than  35  kg/m2),  Age  (greater
than 50), Neck circumference (greater than 40
cm),  and  Gender  (male).  Patients  receive  a
point for each positive risk factor, and those
whose scores are equal to or greater than 3
have a higher likelihood of having OSA. The
sensitivities of the STOP BANG questionnaire
for  mild,  moderate,  and  severe  sleep  apnea
were 83.6%, 92.9%, and 100%, respectively.
The physical examination is frequently nor-
mal in patients with OSA, other than the pres-
ence of obesity, an enlarged neck circumfer-
ence,  and/or  structural  craniofacial  bony
abnormalities. There are other medical condi-
tions that may be associated with the develop-
ment  of  OSA,  including  hypothyroidism  and
acromegaly.  Both  are  associated  with
macroglossia and increased soft tissue mass in
the pharyngeal region, and patients should be
routinely screened for these conditions as well. 
Individuals should have a routine evaluation
of their upper airway. The Mallampati score
has been used for years to identify patients at
risk for difficult tracheal intubation. It is now
also  used  commonly  by  sleep  physicians  to
evaluate for risk of OSA. The classification pro-
vides a score of 1 thru 4 based on the anatom-
ic appearance of the airway seen when an indi-
vidual  opens  his  mouth  (Figure  2).  Studies
have shown that for each 1 score increase in
the Mallampati score, the number of apneic
events increase.42
The next step in the assessment is a formal
sleep evaluation. An overnight polysomnogra-
phy (PSG) is recorded during the normal sleep-
ing hours of a patient. Patients sleep 6 to 8
hours before either awakening spontaneously
or being awokened. The goal of the PSG is to
quantify the amount of time spent in various
stages of sleep during the night and to docu-
ment  clinically  relevant  events  such  as  car-
diopulmonary abnormalities and/or changes in
sleep stages. The standard PSG includes limit-
ed multi-channel recording of an individual’s
electroencephalography  (EEG)  to  assess  for
sleep architecture, sleep stages and arousals.
In addition, surface electromyography of the
chin and all four limbs (to assess for move-
ment),  electro-oculogram,  airflow,  pulse
oximetry,  respiratory  effort,  electrocardio-
graphic  (ECG)  tracings,  body  position,  and
snoring are all accumulated.
The  portable  home-based  sleep  study  has
recently emerged as an alternative to the PSG.
It assesses for oximetry, thoracic and abdomi-
nal movements, and body position. The advan-
tage to this study is that it can be performed
overnight  in  the  comfort  of  the  individual’s
home and is more cost effective in comparison
to  the  formal  PSG.  In  one  study,  normal
overnight  oximetry  was  very  sensitive  in
excluding OSA.43,44 However, the main limita-
tion of the portable home sleep study is that it
does not have the EEG component; it is there-
fore not able to assess an individual’s sleep
architecture  and  will  not  be  able  to  assess
arousals based on changes in sleep stages and
can therefore underestimate the prevalence of
OSA. It is thus indicated for use as an alterna-
tive to PSG for the diagnosis of OSA in patients
with a high pretest probability of moderate to
severe OSA and no other comorbid sleep disor-
ders  or  major  comorbid  medical  disorders.45
Patients should be excluded if they have con-
gestive heart failure, chronic obstructive pul-
monary disease, neuromuscular disease, use
certain medications (potent narcotics), or may
have another suspected causes for sleepiness.
Diagnosis
The American Academy of Sleep Medicine
(AASM) defines an apnea as a cessation in air-
flow lasting at least 10 sec; apneic episodes
can last anywhere from 10 sec to min, and may
occur multiple times per hour.46 Hypopnea is
defined as a recognizable transient reduction
(but not complete cessation) of breathing for
at least10 sec. This differs from apnea in that
there remains some flow of air. In the context
of sleep disorders, a hypopnea event is only
considered to be clinically significant if there
is a 30% or more reduction in flow with an
associated 4% or greater desaturation in O2
level, lasting for 10 seconds or longer, or if it is
associated with an arousal or fragmentation of
sleep. Apneas and hypopneas are both consid-
ered  in  assessing  the  severity  of  a  person’s
sleep disorder.47
The  Apnea-Hypopnea  Index  (AHI)  is  an
index  used  to  assess  the  severity  of  sleep
apnea based on the total number of apneas and
hypopneas occurring per hour of sleep. In gen-
eral, an individual is considered to have an
OSA syndrome if they demonstrate an AHI of at
least 5 with the presence of daytime symptoms
or AHI of 15 or more independent of symptoms.
The AHI can also be used to stratify the sever-
ity of the disease; an AHI of 5-15 is classified
as  mild,  15-30  is  considered  moderate,  and
greater than 30 is considered severe.48
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Figure  2.  Mallampati
score.  Author  Jmarchn.
January  29,  2011.
Permission  is  granted  to
copy,  distribute  and/or
modify  this  document
under  the  terms  of  the
GNU  Free  Documenta  -
tion  License,  Version  1.2
or any later version pub-
lished by the Free Software
Foundation.  [online]
Available  from:  http://en.
wikipedia.org/wiki/Malla
mpati_score. Another measure that is often used is the
Respiratory Disturbance Index (RDI). Like the
AHI, RDI measures respiratory events; howev-
er,  it  also  includes  respiratory  event  related
arousals  (RERAs).  RERAs  are  arousals  from
sleep that do not technically meet the defini-
tions of apneas or hypopneas, but do disrupt
sleep. Some research studies have found that
30% of symptomatic patients would have been
left untreated if the AHI were used rather the
RDI.49 Please  see  Figure  5  for  a  simplified
guideline  for  the  evaluation,  diagnosis  and
appropriate treatment options for OSA man-
agement.
Complications and comorbidities 
Untreated, OSA can have a profound effect
on  the  body  and  can  contribute  to  multiple
health problems (Table 2). It is associated with
cardiovascular  disease,50,51 hypertension,52-54
stroke,55 arrhythmias, and insulin resistance.
Patients with OSA have a 30% higher risk of
heart attack or death than those unaffected.58
Hypertension that is primarily caused by OSA
(in contrast to essential hypertension) is dis-
tinctive  in  that  the  blood  pressure  does  not
drop significantly when the individual is sleep-
ing.59 OSA  that  remains  untreated  can  also
have a negative effect on memory. Research
has recently shown that individuals with OSA
have mammillary bodies that were nearly 20
percent smaller on MRI.60 This decreased tis-
sue mass may be related to the memory prob-
lems seen in chronic OSA.
OSA  can  have  broader  cognitive  impair-
ments, including sustained attention, working
memory, visuospatial learning, motor perform-
ance, and executive functioning.61,62 In partic-
ular, patients with OSA have been shown to
have  impaired  judgment,  prolonged  reaction
time  and  vision  problems,  all  of  which  can
compromise  work  and  driving  ability.63 OSA
increases motor vehicle accident risk by 2- to
3-fold,  independent  of  EDS  or  AHI  score.64
Behavior  and  mood  can  also  be  profoundly
affected by a lack of the adequate restful sleep
seen  in  sleep  apnea,  including  irritability,
aggressiveness, lack of attentiveness, as well
as depression.65
There  has  been  increasing  recognition  of
OSA as a comorbid condition in a number of
neurological  disorders,  including  epilepsy,
stroke, multiple sclerosis, and headache. OSA
appears to be more prevalent in patients with
epilepsy  than  in  the  general  population  and
untreated  OSA  may  theoretically  worsen
seizure control by increasing seizure burden
through  sleep  disruption/deprivation.66 OSA
also increases the risk of stroke and appears to
compromise rehabilitation following strokes.67
It  is  theorized  that  OSA  may  directly  cause
direct neural injury or cause extension of vas-
cular penumbra via hypoxia and ischemia in
stroke.68
There appears to be a higher incidence of
OSA in the multiple sclerosis (MS) population,
but  this  has  been  poorly  studied  in  small
prospective series. It is unclear at this time if
this  comorbidity  association  is  due  to  MS
lesions,  symptomatic  medications  used  for
pain and spasticity, etc.69Chronic and morning
headaches are a relatively common symptom
in OSA, and OSA may aggravate the frequency
and severity of migraines.70OSA treatment has
been shown to reduce cluster headache fre-
quency  in  patients  with  OSA  and  comorbid
cluster headaches.71 The conclusion regarding
OSA as a comorbid condition in some neuro-
logical disorders is that neurologists should be
mindful of the fact that OSA is more prevalent
in their patient population and that practition-
ers should routinely screen for OSA in their
patients.
Treatment options
The most common first step in the treat-
ment  of  mild  OSA  is  behavioral  or  lifestyle
modification, including losing weight, avoid-
ing alcohol, sleep aids or muscle relaxants, and
quitting smoking.72 Weight loss in overweight
patients has been shown to decrease apneic
episodes,72,73 both  directly  and  by  reducing
neck fat and nasopharyngeal crowding.75,76
If an individual’s apneic episodes are mild
and  occur  mainly  during  supine  sleep,  then
patients are advised to take measures to avoid
sleeping supine.77,78 The most common posi-
tion  that  apneic  and  hypopnic  episodes  are
observed during sleep is in the supine posi-
tion.  These  patients  may  also  benefit  from
sleeping at a 30-degree incline.79 Both these
steps may help prevent the tongue and palate
from falling backwards and prevents the gravi-
tational collapse of the airway.
Along with lifestyle modifications, there are
other treatment options of OSA.
Positive airway pressure
For moderate to severe sleep apnea, the use
of  a  continuous  positive  airway  pressure
(CPAP) is the first line therapy.80 CPAP uses
continuous  pressurized  air  flow  to  keep  the
individual’s  airway  open  during  sleep.  The
amount  of  pressure  used  is  initially  titrated
during  the  PSG  (split  test)  based  on  the
patient’s comfort and lowest pressure required
to  decrease  apneic  and  hypopneic  episodes.
CPAP therapy is the most effective treatment
option  in  reducing  apneas  in  OSA.81 It  has
been shown to improve AHI, RDI, sleep archi-
tecture,  EDS,  neurobehavioral  performance
and cardiovascular morbidity (hypertension).
However, noncompliance is common and may
be  as  high  as  40%,  due  mainly  to  discom-
fort.82,83
Newer models of CPAP devices humidify the
air,  which  decreases  dry  mouth  and  makes
usage more comfortable.84 In addition, newer
models have automatic positive airway pres-
sure  options.  This  modality  automatically
titrates the amount of pressure delivered to the
patient to the minimum required to maintain
an unobstructed airway on a breath-by-breath
basis  by  measuring  the  resistance  in  the
patient's breathing, thereby giving the patient
the  precise  pressure  required  at  a  given
time.85
BiPAP (variable/bilevel positive airway pres-
sure) provides two levels of pressure: a higher
inspiratory  positive  airway  pressure  (IPAP)
and a lower expiratory positive airway pres-
sure (EPAP) for easier exhalation. This modal-
ity appears to be better tolerated and individu-
als may find it easier to use; it is used in cases
when  patients  cannot  tolerate  CPAP,  for
patients with chronic CO2 retention as well as
sleep apnea, and for patients with neuromus-
cular disease who need some assistance with
nocturnal ventilation. BiPAP may also be more
useful in CSA.86
Dental appliances
Dentists specializing in sleep dentistry can
make a custom-made mouthpiece that shifts
the lower jaw forward, thereby maintaining an
open airway (in theory). This approach can be
successful in individuals with mild to moder-
ate OSA but has been proven less effective for
severe cases.87 In one study comparing CPAP
to dental appliance in mild to moderate OSA,
dental  appliances  decreased  AHI  from  21
(baseline) to 14, compared to a decreased AHI
of 5 in patients using CPAP.88
Surgery
Surgical treatment for OSA needs to be indi-
vidualized in order to address all anatomical
areas of obstruction. The most frequently uti-
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Table 2. Long term health problems associ-
ated  with  untreated  obstructive  sleep
apnea.










Worsening of Attention Defficit Hyperactivity
Disorder (ADHD)lized  surgery  treatment  is  the  uvu-
lopalatopharyngoplasty (UPPP or UP3). These
surgeries aim to address pharyngeal obstruc-
tion  by  removing  tissue  in  the  back  of  the
throat,  including  part  of  the  uvula,  the  soft
palate, the tonsils, the adenoids and pharynx
(Figure 3). In a retrospective review compar-
ing  CPAP  to  surgery,  there  appeared  to  be
superior  results  with  CPAP  compared  to
UPPP.89 Further studies have not been conclu-
sive  that  this  surgery  has  been  effective  at
treating severe OSA.90
Maxillomandibular advancement (MMA) is
another type of surgery that has been used to
treat OSA. This procedure aims to advance the
maxilla and mandible, thereby pulling forward
the anterior pharyngeal tissues attached to the
maxilla,  mandible  and  hyoid  to  structurally
enlarge  the  retrolingual  and  retropalatal
spaces (Figure 4).91 It is considered the most
effective surgery for OSA patients, because it
increases  the  posterior  airway  space.92 In  a
study in 2008, it was noted that MMA surgery
led to a significant increase in general produc-
tivity, social outcome, activity level and sex.93
In  addition,  there  are  specialized  tech-
niques that are available for correction of spe-
cific  regions  or  obstruction,  including  the
nasal passages (septoplasty and turbinate sur-
gery), the soft palate (implantation of Dacron
pillars) and the tongue. However, there have
not been clinical trials or current evidence to
support  the  use  of  these  techniques  in  the
treatment of OSA.
Pharmacological management
Medications are generally not a part of the
primary  treatment  of  OSA.  Modafinil  is
approved by the FDA for use in patients with
OSA  who  have  residual  daytime  sleepiness.
Armodafinil, the R-enantiomer of modafinil, is
now  FDA  approved  for  use  as  well.  The
American Academy of Sleep Medicine (AASM),
in a clinical review of medical therapies for
OSA,  recommended  Modafinil  as  a  standard
treatment  of  residual  excessive  daytime
sleepiness in patients with OSA despite maxi-
mal  management  of  CPAP.  Protriptyline  was
not recommended as a primary treatment for
OSA, although it was acknowledged that it may
induce moderate improvement in the AHI in
patients with OSA and may be used as a second
line  treatment  option.  Aminophylline,  theo-
phylline, SSRIs and estrogen were not recom-
mended  for  treatment  of  patients  with  OSA
given that there was no consistent evidence of
their effectiveness.94
Conclusions
In the context of the current epidemic of
obesity, the prevalence and consequences of
OSA will likely increase in the coming years.
Given  the  aging  population,  the  number  of
neurological patients with OSA and comorbid
stroke,  epilepsy,  headache,  and  cognitive
decline will also likely rise. OSA can signifi-
cantly affect physical health, mental health and
emotional  well-being.  Fortunately,  screening
methods for sleep apnea have improved, and
there are now very effective means of diagno-
sis and treatment. Treatment can lead to a ben-
eficial impact on a patient’s health and quality
of  life.  Several  treatment  options  exist,  and
research into additional options continues.
The medical community faces many hurdles
regarding the development of adequate early
screening and appropriate treatment of OSA.
An important next steps in understanding and
treating OSA is to be proactive and develop bet-
ter  screening  methods  and  properly  treat
patients at risk (Figure 5).
It is imperative that the medical communi-
ty understand that the effects of OSA is far-
reaching,  and  early  detection/treatment  will
be beneficial to individual patients, as well as
a  cost-effective  public  health  measure  to
reduce morbidity and mortality. Physicians of
all specialties should screen for the presence
of sleep disturbances and consider referral to
a  sleep  specialist  when  indicated.
Neurologists, in particular, should be mindful
of comorbid OSA in their patient population,
since prompt identification and treatment of
OSA may reduce health risk and improve neu-
rological functioning.
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